July 31, 2025 – Talk Bio

Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications

7 days ago talkbio0Tagged China, Clinical Trials, Dosage Forms, Ecosystem, global drug development, Industry, innovation, Legal patent, US-China competition

China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition

ImmuneOnco and Instil Bio’s PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

7 days ago talkbio0Tagged Bio, Combined, Frequency of Responses, IMM2510/AXN-2510, ImmuneOnco, Instill - dosing instruction imperative, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-L1xVEGF, Pharmacotherapy, safety profile

ImmuneOnco; Instil Bio; IMM2510/AXN-2510; PD-L1xVEGF bispecific antibody; NSCLC; Phase 2 clinical trial; response rate; safety profile; chemotherapy combination; lung cancer

Lilly’s Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval

7 days ago talkbio0Tagged Cardiovascular system, Diabetes Mellitus, Non-Insulin-Dependent, dulaglutide, eli lilly, expansion, Hemoglobin A1c measurement, MACE-3, Mortality Vital Statistics, Mounjaro, non-inferiority, outcomes, SURPASS-CVOT, Trulicity, United States Food and Drug Administration, Weight Loss

Mounjaro; tirzepatide; Eli Lilly; cardiovascular outcomes; type 2 diabetes; SURPASS-CVOT; Trulicity; dulaglutide; major adverse cardiovascular events (MACE-3); non-inferiority; A1C reduction; weight loss; mortality; FDA expansion

Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push

7 days ago talkbio0Tagged Biotechnology, COVID-19 Vaccines, Financial savings, layoffs, Moderna, Stéphane Bancel

Moderna; layoffs; workforce reduction; cost-cutting; $1.5 billion savings; 2025; Stéphane Bancel; biotechnology; COVID-19 vaccine

AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology

7 days ago talkbio0Tagged AbbVie, Advice, earnings, Neuroscience discipline, Obesity, PD-1/VEGF, Strategic Deals

AbbVie; 2025 guidance; earnings; neuroscience; obesity; PD-1/VEGF; strategic deals; pharmaceuticals

FDA Seeks Greater Alignment Between CBER and CDER: Makary Informs Industry Leaders

7 days ago talkbio0Tagged Biological Factors, CBER, CDER, Cells, Drug Industry, gene therapy, George Tidmarsh, Makary, Marty, Prasad, regulatory harmonization, United States Food and Drug Administration

FDA; CBER; CDER; regulatory harmonization; Marty Makary; George Tidmarsh; Vinay Prasad; cell and gene therapy; biologics; pharmaceutical industry

Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas

1 week ago talkbio0Tagged Alzheimer 's disease, BROADWAY trial, Cardiff Oncology, Clinical Trials, Metastasis from malignant neoplasm of colon and/or rectum, Neoplasms, NewAmsterdam Pharma, onvansertib, Statistical Significance, Vyne

Cardiff Oncology; VYNE; NewAmsterdam Pharma; clinical trial updates; onvansertib; metastatic colorectal cancer; Alzheimer’s disease; BROADWAY trial; oncology; statistically significant results

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

1 week ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal